Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
SAIL Fusion
Del Mar, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
SAIL Fusion's BowTie Sacroiliac Fusion System received FDA clearance in 2024 and began limited U.S. commercial release, with encouraging initial clinical results showing robust joint fusion and early patient benefit. The BowTie technology uniquely applies AO joint fusion principles, featuring intra-articular and transfixing components for maximal biomechanical fixation and optimal osteointegration.[2][4][5][6]
- Therapeutic areas
- Rheumatology
- Modalities
- Device
- Industry
- Implantable Medical Devices
Beyond the preview
Go deeper on SAIL Fusion.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAIL Fusion.